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MaBACKGROUND The ﬁrst CE-approved bioresorbable vascular scaffold (BVS) is effective at treating simple lesions and
stable coronary artery disease, but it has yet to be assessed versus the best-in-class drug-eluting stents (DES).
OBJECTIVES This study sought to compare the performance of a BVS with that of everolimus-eluting stents (EES) and
biolimus-eluting stents (BES) in all-comer patients.
METHODS The EVERBIO II (Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bio-
resorbable Vascular Scaffold Stents II) trial was a single-center, assessor-blinded study of 240 patients randomly
assigned in a 1:1:1 ratio to EES, BES, or BVS. The only exclusion criterion was a reference vessel diameter >4.0 mm, which
precluded treatment with BVS. The primary endpoint was angiographic late lumen loss (LLL) at 9 months. Secondary
endpoints included patient-oriented major acute coronary events (MACE) (death, myocardial infarction [MI], and any
revascularization), device-oriented MACE (cardiac death, MI, and target lesion revascularization), and stent thrombosis at
the 9-month clinical follow-up.
RESULTS Follow-up angiography was performed in 216 patients (90.7%) at 9 months. In-stent LLL was similar between
patients treated with BVS (0.28  0.39 mm) and those treated with EES/BES (0.25  0.36 mm; p ¼ 0.30). Clinical
outcomes were similar at 9 months: the patient-oriented MACE rate was 27% in BVS and 26% in the EES/BES group
(p ¼ 0.83) and the device-oriented MACE rate was 12% in BVS and 9% in the EES/BES group (p ¼ 0.6).
CONCLUSIONS New-generation metallic DES (EES/BES) were not superior to BVS in terms of angiographic LLL and
clinical outcomes. (Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable
Vascular Scaffold Stents [EVERBIO II]; NCT01711931) (J Am Coll Cardiol 2015;65:791–801) © 2015 by the
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ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndrome(s)
ARC = Academic
Research Consortium
BES = biolimus-eluting stent(s)
BVS = bioresorbable vascular
scaffold stent(s)
DES = drug-eluting stent(s)
EES = everolimus-eluting
stent(s)
LLL = late lumen loss
MACE = major adverse
coronary event(s)
MI = myocardial infarction
PCI = percutaneous
coronary intervention
ST = stent thrombosis
TLR = target lesion
revascularization
TVR = target vessel
revascularization
Puricel et al. J A C C V O L . 6 5 , N O . 8 , 2 0 1 5
The EVERBIO II Trial M A R C H 3 , 2 0 1 5 : 7 9 1 – 8 0 1
792neoatherogenesis (2). Not surprisingly, re-
search and development in the ﬁeld of inter-
ventional cardiology has concentrated on
more biocompatible stents.SEE PAGE 802From these innovations, the second-
generation everolimus-eluting stent (EES)
using a biocompatible durable polymer (ﬂuo-
rinated copolymer) with thin strut (81 mm) and
the third-generation biolimus-eluting stent
(BES) using an abluminally coated biode-
gradable polymer (polylactic acid) with rela-
tively thick strut (112 mm) are currently
considered the safest DES. Several trials have
demonstrated the superiority of both EES and
BES over earlier generations of DES in long-
term clinical outcomes (3–10). Outcomes
were similar, however, when EES was com-
pared with BES (11,12). Furthermore, Natsuaki
et al. (13) found BES to be noninferior to
EES for in-stent late lumen loss (LLL) at
8 months.More recently, everolimus-eluting bioresorbable
vascular scaffold stents (BVS) have been developed
with the aim to further improve late outcomes. The
Absorb device (Abbott Vascular, Santa Clara, Califor-
nia) is the ﬁrst CE-approved BVS. The prospective,
open-label, 2-stage ABSORB study of 131 patients was
conducted in Europe and New Zealand and led to
approval of the Absorb BVS by the European Union in
January 2011 to treat coronary artery lesions (14). The
reported LLL was 0.27 mm at 12 months, and the
composite endpoint major acute coronary event
(MACE) rate was 6.8% at 2-year follow-up (15,16).
Due to its resorption kinetics, BVS radial strength is
disturbed 6 to 12 months after implantation. This
phenomenon could be responsible for the higher
restenosis rate compared with metallic platforms at
midterm, especially in complex lesions. Its non-
inferiority to EES is currently under investigation in
the multicenter randomized ABSORB II trial, in which
500 patients are anticipated to enroll (17). Published
head-to-head data on BVS compared with EES or
BES are lacking. We therefore sought to compare
the efﬁcacy, at midterm, of the Absorb BVS, the
Promus Element EES (Boston Scientiﬁc, Marlborough,
Massachusetts), and Biomatrix Flex BES (Biosensors
Europe SA, Morges, Switzerland) using LLL as an early
marker of restenosis (18,19) in all-comer patients.
Assuming similar outcomes for the primary endpoint
of LLL between BES and EES as suggested by the NEXT
(Nobori Biolimus-Eluting Versus Xience/Promus
Everolimus-Eluting Stent Trial) (13), COMPARE II(A Trial of Everolimus-Eluting Stents and Paclitaxel-
Eluting Stents for Coronary Revascularization in
Daily Practice II) (11), and EVERBIO (Everolimus-
Versus Biolimus-Eluting Stents in All-Comers) trial
(12), which demonstrated similar target lesion revas-
cularization (TLR) rates, both DES were uniﬁed as
1 comparator.
METHODS
STUDY DESIGN AND PATIENTS. EVERBIO II was a
single-center, assessor-blinded, randomized study
(20). Between November 2012 and November 2013,
240 patients 18 years of age or older, capable of
providing informed consent, with symptomatic cor-
onary artery disease or silent ischemia were
recruited at the Fribourg University and Hospital
(Switzerland). The study protocol deﬁned no limit
for lesion length, number of target lesions, or
number of vessels. The only exclusion criterion was
a reference vessel size >4.0 mm that would have
prevented the implantation of BVS. Patients with a
known or presumed hypersensitivity to heparin,
antiplatelet drugs, or contrast dye not controllable
with standard premedication were excluded. The
EVERBIO II study complied with the Helsinki
Declaration and was approved by the local ethics
committee of Fribourg University and Hospital
(043/12-CER-FR). All patients provided written,
informed consent for participation.
Patient randomization was performed after lesion
preparation on the basis of computer-generated ran-
dom numbers. Allocation was concealed in sealed
nontransparent numbered envelopes. Only the
outcome assessors and data analysts were blinded to
the intervention.
The Absorb BVS (Abbott Vascular) has a poly-
DL-lactide coating releasing everolimus. The scaffold
body is semi-crystalline poly-L-lactide, which is
completely degraded via hydrolysis and bioresorbed
within 2 years via the Krebs cycle. The scaffold has
150-mm struts.
The Promus Element stent (Boston Scientiﬁc)
consists of a platinum chromium alloy with ever-
olimus (100 mg/cm2) applied in a durable, biocom-
patible acrylic polymer and ﬂuorinated copolymer.
The Biomatrix Flex stent (Biosensors Europe SA)
consists of stainless steel (strut thickness of 112 mm)
with only abluminal coating with a biodegradable
polymer layer (20 mm) that dissolves 6 to 9 months
after implantation and from which the lipophilic
antiproliferative drug biolimus elutes.
Procedures were performed via the femoral or
radial artery with a 5-F to 6-F guiding catheter.
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793Standard interventional techniques were used and
performed according to practice guidelines. A pre-
procedural antithrombotic regimen was systemati-
cally achieved with aspirin (500 mg intravenous bolus
for those not under treatment and 100 mg for those
already on aspirin and then 100 mg/day for all)
and unfractionated heparin (70 UI/kg), whereas a
glycoprotein IIb/IIIa inhibitor was administered per
operator discretion. All patients received either a
minimum 600-mg loading dose of clopidogrel, 180 mg
of ticagrelor, or 60 mg of prasugrel before or imme-
diately after the procedure. Lifelong $100 mg daily
aspirin and 75 mg daily clopidogrel, 90 mg twice daily
ticagrelor, or 10 mg prasugrel for a minimum of 6
months were prescribed. For patients receiving oral
anticoagulation therapy, we prescribed 100 mg of
aspirin once daily for a minimum of 1 month and
clopidogrel 75 mg daily for 12 months in addition to
oral anticoagulation. Other medications were pre-
scribed per standard of care. All patients were moni-
tored for 4 to 12 h in an intermediate care unit
and underwent baseline and 3- to 6-h car-
diac biomarker measurements. A standard 12-lead
electrocardiogram was recorded before and immedi-
ately after the procedure and with each biomarker
measurement.
STUDY ENDPOINTS. The primary angiographic
endpoint was in-stent LLL at 9 months. Based on
previous reports (21,22), comparison of LLL between
the BVS and EES or BES at 9 months would represent
the “most unfavorable” timing for the bioabsorbable
scaffold and would thus provide important informa-
tion regarding its clinical effectiveness. The second-
ary angiographic endpoints were in-segment LLL,
binary restenosis at 9 months, acute gain, minimal
lumen diameter, and percent diameter stenosis.
The secondary clinical endpoints included a
patient-oriented MACE rate (composite of death,
myocardial infarction [MI], and any revasculariza-
tion), a device-oriented MACE (composite of cardiac
death, MI, and TLR), and stent thrombosis (ST) at
1 year. All clinical endpoints were deﬁned according
to Academic Research Consortium (ARC) criteria (23).
Peri-procedural MI was deﬁned according to the
Global MI Task Force for the Universal Deﬁnition of
Myocardial Infarction (24). Death was considered of
cardiac origin when due to proximate cardiac cause,
unwitnessed death, or death of unknown cause. TLR
was deﬁned as repeat revascularization within the
stent or the 5-mm boarders proximal and distal to
the stent. Target vessel revascularization (TVR) was
deﬁned as any revascularization in the stented vessel.
TVR or TLR was considered ischemia driven ifassociated with a positive functional study, target
vessel diameter, or stenosis $50% by core laboratory
quantitative analysis with ischemic symptoms or a
target vessel (or lesion) diameter stenosis $70% with
or without documented ischemia. MI was deﬁned as
either the development of new pathological Q
waves $0.04 s in duration in $2 contiguous leads or
an elevation of creatine phosphokinase levels to
>2 times normal with positive creatine phosphoki-
nase–MB or troponin I levels. ST was considered
deﬁnite if there was angiographic conﬁrmation of
thrombus, with or without vessel occlusion, associ-
ated with clinical or electrocardiographic signs of
acute ischemia or elevation of creatine kinase
levels to twice the normal value within 48 h of angi-
ography. ST was classiﬁed as probable if unexplained
death occurred within 30 days after the index proce-
dure or if MI, occurring at any time after the index
procedure, was documented in an area vascularized
by the target vessel in the absence of angiographic ST
conﬁrmation. ST was considered possible in any
unexplained death occurring more than 30 days after
intracoronary stenting until end of follow-up.
Coronary angiograms were digitally recorded at
baseline, immediately after the procedure, and at
follow-up and were assessed at the angiographic core
laboratory of the University of Fribourg. Angiogram
readers were noncardiologists and were unaware of
study endpoints. The projection that best showed the
stenosis was used for all analyses. Patients received
nitroglycerin before angiography, and measurements
were performed on cineangiograms. The contrast-
ﬁlled, nontapered tip of the catheter was used for
calibration. Digital angiograms were analyzed with
the use of an automated edge detection system
(CAAS II, Pie Medical Imaging, Maastricht, the
Netherlands). LLL was deﬁned as the difference be-
tween the minimum lumen diameter post-procedure
and at 9 months. In-stent was considered for
measurements in the implanted stent, whereas
in-segment embraced the complete target lesion in
cases of multiple stent implantations. Binary reste-
nosis was deﬁned as >50% diameter stenosis. Any
unscheduled angiogram after 6 months was consid-
ered as 9-month follow-up angiogram.
All in-hospital events were recorded before
discharge. Clinical follow-up was scheduled at 3, 6, 9,
and 12 months and at 2 and 5 years. If the patient was
not accessible, data were retrieved from the referring
physician or the hospital electronic database. An
independent Clinical Events Adjudication Committee
(CEAC), including interventional and noninter-
ventional cardiologists, reviewed and adjudicated
all reported events and endpoints and performed
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CEAC members were blinded to stent allocation.
STATISTICAL ANALYSES. This trial was powered for
superiority of DES over BVS for the primary endpoint
of LLL at 9 months. On the basis of published LLL
data, we assumed a difference of 0.2 mm in LLL at 9
months (BES/EES 0.3 mm vs. BVS 0.5 mm; SD
0.5 mm). Of note, the assumed LLL of 0.5 mm in the
BVS group was based on: 1) the hypothesis that LLL
would be maximal at 6 to 12 months (LLL of 0.7 to 0.9
mm, with a peak in pigs at 3 to 6 months) (21); and 2)
the hypothesis that LLL would be greater in complex
lesions such as in the EVERBIO II trial than that
expected in simple lesions such as in the ABSORB B
cohort (LLL of 0.2 mm at 6 months) due to a higher
rate of scaffold recoil (with or without premature
fracture) (22). On the basis of these criteria, the
sample size of 240 patients was considered to achieve
a power of 90%. This allowed for a dropout rate of
20%, in which case the study would still yield a power
of 83%. Sample size calculations were performed us-
ing Sample Power 3 (SPSS Inc., Chicago, Illinois) at a
2-tailed signiﬁcance level of alpha ¼ 0.05.
Baseline and procedural characteristics, as well
as angiographic and clinical outcomes, were com-
pared between patients receiving BVS and patients
receiving EES/BES.
Categorical variables are reported as counts and
percentages; continuous variables are reported as
mean and SD or as median with 25% to 75% inter-
quartile range according to their distribution.
Normality was assessed by visual inspection of his-
tograms and the computation of Q-Q plots. Categori-
cal variables were compared using chi-square or
Fisher exact test as appropriate. Continuous variables
were analyzed using the Student t test or the Wil-
coxon rank-sum test according to their distribution.
For quantitative coronary angiography, data are re-
ported as mean and SD, regardless of distribution.
Pre-speciﬁed stratiﬁed analysis was performed
according to the presence/absence of diabetes, acute
coronary syndrome (ACS), and complex lesions. Sur-
vival free from the occurrence of clinical endpoints
was compared using the log-rank test and plotted as
Kaplan-Meier survival functions.
All statistical analyses were performed using
dedicated software (Stata version 13, StataCorp LP,
College Station, Texas) at a 2-tailed signiﬁcance level
of alpha ¼ 0.05.
RESULTS
Figure 1 depicts patient ﬂow. A total of 240 patients
were enrolled and randomized to BVS (n ¼ 80), EES(n ¼ 80), or BES (n ¼ 80) implantation. Two pa-
tients randomized to BVS were excluded due to
important protocol violations (did not receive study
stent). The total dropout rate was 9.2%, with 8
(10%) in the EES, 5 (6.3%) in the BES, and 9 (11.5%)
in the BVS groups who withdrew consent for follow-
up angiography; 216 patients (90.8%) underwent
9-month follow-up angiography. Baseline clinical
characteristics were similar in both groups (Table 1).
Mean age of participants was 65  11 years, a ma-
jority of whom were men (79%); 23% had diabetes,
17% a prior history of MI, and 31% had already
undergone PCI. The clinical presentation was ACS in
39% of cases.
The baseline angiographic and procedural char-
acteristics were generally well balanced (Table 2).
Pre-procedural dimensions were similar except for
reference vessel diameter (BVS 2.77  0.60 mm vs.
EES/BES 2.46  0.78 mm; p < 0.01). Signiﬁcant
differences in PCI technique between BVS and
EES/BES were observed: less direct stenting (3% vs.
17%; p < 0.01); higher incidence of hybrid PCI
(deﬁned as the concomitant implantation of 1
study and 1 nonstudy stent in the same lesion;
4% vs. 1%; p ¼ 0.03); trend toward longer scaffold
(22.8  8.8 mm vs. 20.7  12.1 mm; p ¼ 0.08)
of greater diameter (3.13  0.37 mm vs. 2.99 
0.82 mm; p ¼ 0.03).
Immediate post-procedural results are summarized
in Table 3. Due to the longer scaffold with greater
diameter, in-segment dimensions tended to be
greater after BVS implantation than after EES/BES
implantation. On the other hand, due to greater acute
recoil in BVS (9.5  6.5% vs. 6.6  4.7%; p < 0.01),
post-procedural in-stent dimensions tended to be
lower with BVS compared with EES/BES.
At 9 months, the primary angiographic endpoint of
in-stent LLL was similar in both groups, with 0.28 
0.39 mm for BVS and 0.25  0.36 mm for EES/BES
(difference 0.04 mm; 95% CI: 0.06 to 0.13; p ¼ 0.30).
There was no difference for in-stent LLL between EES
and BES (p ¼ 0.75). Angiographic ﬁndings are depic-
ted in the Central Illustration and Figure 2. Stratiﬁed
analyses of in-stent LLL did not reveal signiﬁcant
differences in treatment effects between patients
with and without diabetics (p for interaction ¼ 0.33)
nor between patients with and without ACS (p for
interaction ¼ 0.28). Moreover, treatment effect was
not different for complex versus simple lesions (p for
interaction ¼ 0.94).
Furthermore, we performed a post-hoc non-
inferiority analysis based on the noninferiority
margin published in the NEXT trial (0.195 mm) (13).
The inclusion of 240 patients with an unequal
TABLE 1 Baseline Patient Characteristics
EES
(n ¼ 80)
BES
(n ¼ 80)
EES and BES
(n ¼ 160)
BVS
(n ¼ 78)
p Value
EES vs. BVS BES vs. BVS EES/BES vs. BVS
Male 64 (80) 64 (80) 128 (80) 61 (78) 0.78 0.78 0.75
Age, yrs 65  11 65  10 65  11 65  11 0.78 0.99 0.88
Hypertension 51 (64) 50 (63) 101 (63) 43 (55) 0.27 0.35 0.24
Diabetes 13 (16) 26 (33) 39 (24) 17 (22) 0.37 0.13 0.66
Non–insulin dependent 8 (10) 21 (26) 29 (18) 17 (22) 0.04 0.51 0.50
Smoking 30 (38) 25 (31) 55 (34) 28 (36) 0.83 0.54 0.82
Dyslipidemia 50 (63) 52 (65) 102 (64) 44 (56) 0.44 0.27 0.28
Family history of CAD 23 (29) 23 (29) 46 (29) 23 (30) 0.92 0.92 0.91
Previous PCI 25 (31) 23 (29) 48 (30) 25 (32) 0.91 0.65 0.75
Previous CABG 11 (14) 16 (20) 27 (17) 6 (8) 0.22 0.03 0.07
Previous MI 14 (18) 16 (20) 30 (19) 11 (14) 0.56 0.33 0.37
Indication for index procedure 0.74 0.14 0.72
Unstable angina 5 (6) 9 (11) 14 (9) 6 (8)
NSTEMI 16 (20) 21 (26) 37 (23) 13 (17)
STEMI 6 (8) 8 (10) 14 (9) 9 (12)
Stable angina 47 (59) 27 (34) 74 (46) 41 (53)
Silent ischemia 6 (8) 15 (19) 21 (13) 9 (12)
LVEF, %* 60 (55-65) 58 (45-65) 60 (48-65) 61 (50-66) 0.74 0.19 0.35
Values are n (%), mean  SD, or median (interquartile range). *LVEF as assessed with ultrasound, cardiac magnetic resonance imaging, or left ventricular angiography.
BES ¼ biolimus-eluting stent(s); BVS ¼ bioresorbable vascular scaffold stent(s); CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; EES ¼ everolimus-
eluting stent(s); LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼ percutaneous coronary
intervention; STEMI ¼ ST-segment elevation myocardial infarction.
FIGURE 1 Patient Study Flow
Enrolled and randomized
(N=240)
Patients excluded due
to protocol violation
(N=2)
BVS
ABSORB (N=78)
EES
PROMUS ELEMENT (N=80)
BES
BIOMATRIX FLEX (N=80)
6-month
Follow-up
Clinical 100%
(N=78)
Clinical 100%
(N=80)
Clinical 100%
(N=80)
9 withdrew
consent
8 withdrew
consent
5 withdrew
consent
9-month
Follow-up
Clinical 100%
(N=78)
Angio 88%
(N=69)
Clinical 100%
(N=80)
Angio 90%
(N=72)
Clinical 98%
(N=78)
Angio 94%
(N=75)
Patients were randomized 1:1:1 to 1 of 3 stent platforms. BES ¼ biolimus-eluting stent(s); BVS ¼ biovascular scaffold stent(s);
EES ¼ everolimus-eluting stent(s).
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TABLE 2 Procedural Characteristics
EES
(n ¼ 80)
BES
(n ¼ 80)
EES and BES
(n ¼ 160)
BVS
(n ¼ 78)
p Value
EES
vs. BVS
BES
vs. BVS
EES/BES
vs. BVS
Vessels diseased per patient 1.9  0.8 1.9  0.8 1.9  0.6 1.9  0.7 0.74 0.67 0.67
Vessels treated per patient 1.2  0.4 1.1  0.4 1.1  0.4 1.1  0.3 0.51 0.83 0.50
Lesions per patient 2.1  1.3 2.2  1.4 2.2  1.3 2.1  1.4 0.98 0.75 0.77
Lesions treated per patient 1.5  0.8 1.4  0.6 1.4  0.7 1.3  0.5 0.3 0.85 0.60
(n ¼ 112) (n ¼ 117) (n ¼ 229) (n ¼ 96)
Target coronary artery 0.31 0.05 0.19
LM 1 (1) 1 (1) 2 (1) 0 (0)
LAD 44 (39) 34 (29) 78 (34) 44 (46)
LCX 21 (19) 27 (23) 48 (21) 24 (25)
RCA 40 (36) 48 (41) 88 (38) 24 (25)
Arterial graft 2 (2) 1 (1) 3 (1) 0 (0)
Vein graft 4 (4) 6 (5) 10 (4) 4 (4)
Type of intervention per lesion
Pure study stent implantation 111 (1) 117 (100) 228 (99) 92 (96) 0.18 0.03 0.03
Hybrid with other DES implantation 1 (1) 0 (0) 1 (1) 4 (4) 0.18 0.03 0.03
Hybrid with BMS implantation 0 (0) 0 (0) 0 (0) 0 (0)
Lesion complexity
A 28 (25) 34 (29) 62 (27) 19 (20) 0.41 0.15 0.21
B1 45 (40) 49 (42) 94 (41) 49 (51) 0.13 0.21 0.11
B2 19 (17) 17 (15) 36 (16) 13 (14) 0.57 1 0.74
C 20 (18) 17 (15) 37 (16) 15 (16) 0.71 0.85 1
TIMI ﬂow post-intervention
per lesion
3 (3-3) 3 (3-3) 3 (3-3) 3 (3-3) 0.35 1 0.52
Restenotic lesion 2 (2) 3 (3) 5 (2) 1 (1) 1.00 0.63 0.50
Chronic total occlusion 7 (6) 5 (4) 12 (5) 1 (1) 0.07 0.16 0.12
Thrombus aspiration 5 (4) 7 (6) 12 (5) 7 (7) 0.38 0.70 0.47
Number of stents per lesion 1.3  0.7 1.1  0.4 1.2  0.6 1.2  0.5 0.04 0.14 0.55
Total stent length per lesion, mm 22.1  13.8 19.3  10.0 20.7  12.1 22.8  8.8 0.67 <0.01 0.08
Maximum stent diameter per lesion, mm 3.0  1.0 3.0  0.6 3.0  0.8 3.1  0.4 0.31 <0.01 0.03
Maximum pressure per lesion, atm 14.6  2.9 13.8  3.0 14.2  3.0 13.6  2.8 0.04 0.67 0.09
Overlapping stents per lesion 26 (23) 14 (12) 40 (17) 16 (17) 0.24 0.33 0.86
Direct stenting per lesion 16 (14) 23 (20) 39 (17) 3 (3) <0.01 <0.01 <0.01
Post-dilation per lesion 35 (31) 35 (30) 70 (31) 33 (34) 0.63 0.49 0.50
Values are mean  SD, n (%), or median (interquartile range).
BMS ¼ bare-metal stent(s); DES ¼ drug-eluting stent(s); LAD ¼ left anterior descending; LCX ¼ left circumﬂex; LM ¼ left main; RCA ¼ right coronary artery;
TIMI ¼ Thrombolysis In Myocardial Infarction; other abbreviations as in Table 1.
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796treatment assignment of 2:1 would have yielded a
power of 82% to detect noninferiority at a 1-sided
alpha level of 0.025 with a noninferiority margin
of 0.195  0.49 mm for the outcomes in both
treatment arms. This retrospective analysis was
done for illustrative purposes only. The difference
of 0.04 mm (95% CI: 0.06 to 0.13) in favor
of the metallic stents signiﬁcantly demonstrated
BVS noninferiority (p ¼ 0.001) for in-stent LLL at
9 months.
The secondary angiographic endpoint of in-
segment LLL, however, was slightly but signiﬁcantly
higher in BVS (0.30  0.44 mm) versus EES/BES
(0.19  0.42 mm; p ¼ 0.03). Taken separately, there
was no difference between EES and BES (p ¼ 0.72).At 9 months, there were no differences in the sec-
ondary endpoints of device-oriented MACE (EES/BES
12% vs. BVS 9%; p ¼ 0.60) or patient-oriented MACE
(EES/BES 26% vs. BVS 27%; p ¼ 0.83). Clinically
driven TLR also was similar, occurring in 6% of pa-
tients receiving EES/BES and 8% of patients receiving
BVS (p ¼ 0.54), as was clinically driven TVR in 8% for
EES/BES and 10% for BVS (p ¼ 0.59). Non-TVR was
similar in both groups, 11% versus 12% (p ¼ 0.83) for
EES/BES and BVS, respectively, and non–target
vessel–related MI occurred once in each group, but
there were no target vessel-related MIs. Overall,
mortality was 2%. One death of unknown cause
occurred in the BVS group at 238 days post-procedure
and was, according to ARC criteria, considered a
TABLE 3 Quantitative Coronary Angiography Measurements
EES
(n ¼ 103)
BES
(n ¼ 106)
EES/BES
(n ¼ 209)
BVS
(n ¼ 75)
p Value*
EES vs. BVS BES vs. BVS EES/BES vs. BVS
Pre-procedure
MLD, mm 0.52  0.42 0.59  0.50 0.55  0.46 0.60  0.58 0.58 0.99 0.75
Diameter stenosis, % 79.78  15.3 78.7  15.3 79.2  15.7 81.3  16.2 0.48 0.30 0.33
RVD, mm 2.39  0.70 2.53  0.84 2.46  0.78 2.77  0.60 <0.01 0.04 <0.01
Post-procedure
MLD, in-stent, mm 2.62  0.40 2.72  0.53 2.67  0.47 2.56  0.43 0.36 0.08 0.18
MLD, in-segment, mm 2.11  0.45 2.24  0.60 2.17  0.53 2.35  0.51 <0.01 0.20 0.01
Diameter stenosis, in-stent, % 8.1  4.8 7.1  5.8 7.6  5.3 9.3  5.7 0.28 <0.01 0.04
Diameter stenosis, in-segment, % 12.9  10.4 12.3  9.4 12.6  9.9 11.8  7.4 0.44 0.50 0.41
Acute gain, in-stent, mm 2.09  0.49 2.12  0.53 2.11  0.51 1.97  0.66 0.47 0.21 0.35
Acute gain, in-segment, mm 1.59  0.49 1.65  0.58 1.62  0.53 1.76  0.73 0.07 0.41 0.12
Acute recoil, % 6.2  4.2 6.9  5.2 6.6  4.7 9.5  6.5 <0.01 <0.01 <0.01
9 months
MLD, in-stent, mm 2.38  0.47 2.57  0.65 2.42  0.56 2.28  0.51 0.17 0.02 0.07
MLD, in-segment, mm 1.91  0.48 2.06  0.63 1.99  0.58 2.05  0.51 0.19 0.86 0.42
Diameter stenosis, in-stent, % 11.3  9.8 12.6  14.9 11.9  12.5 16.9  11.6 <0.01 <0.01 <0.01
Diameter stenosis, in-segment, % 15.5  11.0 16.1  17.2 15.8  14.3 17.8  11.7 0.17 0.01 0.03
RVD, mm 2.68  0.51 2.66  0.48 2.67  0.37 2.83  0.51 0.07 0.04 0.03
Late loss, in-stent, mm 0.24  0.32 0.25  0.41 0.25  0.36 0.28  0.39 0.40 0.31 0.30
Late loss, in-segment, mm 0.20  0.43 0.17  0.40 0.19  0.42 0.30  0.44 0.08 0.03 0.03
Binary restenosis, in-stent 4 (4) 5 (5) 9 (4) 4 (5) 0.64 0.85 0.71
Binary restenosis, in-segment 9 (9) 11 (10) 20 (10) 8 (11) 0.67 1.00 0.78
Values are mean  SD or n (%). *p values are from Fisher exact, Student t test, or Wilcoxon rank-sum test, as appropriate.
MLD ¼ minimal lumen diameter; RVD ¼ reference vessel diameter; other abbreviations as in Table 1.
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797cardiac death as well as possible ST. However, there
was no ARC-deﬁned deﬁnite or probable ST during
follow-up. Clinical outcomes are summarized in
Table 4, Central Illustration, and Figure 3.
DISCUSSION
This randomized, controlled, single-center, assessor-
blinded study investigated the angiographic and
clinical outcomes in 238 patients assigned to BVS,
EES, or BES implantation over a 9-month follow-up
period. The major ﬁnding was no signiﬁcant differ-
ences between the 2 treatment arms for the primary
angiographic endpoint of in-stent LLL at 9-month
follow-up or in any of the secondary clinical end-
points (Central Illustration).
In-stent LLL is considered a particularly robust
endpoint for discrimination of new coronary stents
for which binary rates are anticipated to be low. It
is highly predictive of clinical revascularization
rates, correlating with binary restenosis and TLR, and
especially useful for “early” trials, such as ours, with
limited sample size (19,25).
To better analyze BVS effectiveness in complex
patients, we deliberately chose to compare it with thebest competitors and at its weakest time point. On the
basis of animal evidence, we speculated that BVS
failure would be 6 to 12 months post-implantation. As
reported by Otsuka et al. (21), BVS in-stent LLL
peaked and was signiﬁcantly higher than that of EES
in-stent LLL (6-month LLL: BVS 0.69  0.18 mm vs.
EES 0.38  0.15 mm; p ¼ 0.01) at the 3- to 6-month
follow-up in a mini-pig model but declined there-
after with coronary remodeling (e.g., 42-month LLL:
BVS 0.42  0.35 mm vs. EES 0.12  0.31 mm; p ¼
0.06). This is supported by the following: 1) BVS
resorption kinetics that signiﬁcantly disturb radial
strength and the mechanical aptitude of the plat-
form 6 months after implantation based on the
model of Prabhu and Hossainy (26); and 2) after a
given time point (18 to 24 months based on the
ABSORB [27] and ABSORB-EXTEND [28] trials),
additional beneﬁts are expected from BVS compared
with metallic DES. Among these late putative ad-
vantages are a lowered risk of delayed complications
(ST, neoatherosclerosis), partial restoration of
vasomotion, plaque sealing/capping, and plaque
remodeling/resorption (29).
Our reassuring ﬁndings revealed excellent in-stent
LLL for both groups in a patient population with a
CENTRAL ILLUSTRATION Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With
Everolimus-Eluting Bioresorbable Vascular Scaffolds: Clinical and Angiographic Endpoints
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When compared with contemporary metallic stents, the biovascular scaffold stent (BVS) was noninferior for in-stent late lumen loss but produced signiﬁcantly higher
in-segment late lumen loss. Clinical endpoints relating both to devices and patients were similar between study arms. BES¼ biolimus-eluting stent(s); EES¼ everolimus-
eluting stent(s).
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798substantial number of ACS events and complex lesion
characteristics. The BVS matched the in-stent LLL
and clinical outcomes of the safest DES on the market.
This should be emphasized because EES previously
was demonstrated to be noninferior to sirolimus-
eluting stents and superior to paclitaxel-eluting
stents (3–6).
One propensity score–matched registry (LESSON-1
[Long-Term Comparison of Everolimus-Eluting
and Sirolimus-Eluting Stents for Coronary
Revascularization-1]) showed a trend toward a lowerrisk of death, MI, and TVR with EES compared with
sirolimus-eluting stents during a 3-year follow-up
(7). Similarly, BES proved to be superior to SES at
the 5-year follow-up in the LEADERS (Limus Eluted
From a Durable Versus Erodable Stent Coating) trial,
with fewer episodes of very late ST (0.7% vs. 2.5%;
p ¼ 0.003) and a lower rate of composite clinical
outcomes (10). As suggested by Moreno et al. (18) in
a meta-analysis of 8,641 patients from 21 trials, a
0.1-mm reduction in mean in-stent LLL (DES com-
pared with bare-metal stent) was associated with a
FIGURE 2 Cumulative Frequency Distribution of In-Stent and In-Segment LLL
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At 9 months, metallic stents were not superior to BVS for in-stent late lumen loss (LLL); in-segment LLL was higher with BVS, signiﬁcantly so
versus BES (p ¼ 0.03). Abbreviations as in Figure 1.
TABLE 4 Clinical Outcomes at 9 Months
EES
(n ¼ 80)
BES
(n ¼ 80)
EES/BES
(n ¼ 160)
BVS
(n ¼ 78)
p Value
EES
vs. BVS
BES
vs. BVS
EES/BES
vs. BVS
Device-oriented composite 11 (14) 4 (5) 15 (9) 9 (12) 0.68 0.14 0.60
Cardiac death 0 (0) 0 (0) 0 (0) 1 (1) 0.49 0.49 0.33
MI of the target vessel 0 (0) 0 (0) 0 (0) 0 (0) — — —
TLR 11 (14) 4 (5) 15 (9) 8 (10) 0.50 0.21 0.83
Clinically indicated 7 (9) 2 (3) 9 (6) 6 (8) 0.81 0.16 0.54
Patient-oriented composite 26 (33) 15 (19) 41 (26) 21 (27) 0.44 0.22 0.83
All-cause mortality 3 (4) 0 (0) 3 (2) 1 (1) 0.62 0.49 1.00
Any MI 1 (1) 0 (0) 1 (1) 1 (1) 1.00 0.49 0.55
Repeat revascularization 24 (30) 15 (19) 39 (24) 19 (24) 0.43 0.39 0.99
TVR 14 (18) 8 (10) 22 (14) 11 (14) 0.56 0.43 0.94
Clinically indicated 8 (10) 5 (6) 13 (8) 8 (10) 0.96 0.36 0.59
Stent thrombosis (possible) 0 (0) 0 (0) 0 (0) 1 (1) 0.49 0.49 0.33
Values are n (%).
TLR ¼ target lesion revascularization; TVR ¼ target vessel revascularization; other abbreviations as in Table 1.
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7991.2-fold decrease in the number needed to treat for
TLR (18). Thus, the 0.06-mm increase observed in
the present trial (BVS in-stent LLL compared with
EES/BES in-stent LLL) would indicate a marginal
increase in TLR for the BVS group. Moreover, accu-
mulating evidence demonstrates a late catch-up
phenomenon with metallic DES not yet observed
with BVS.
In-segment LLL was slightly but signiﬁcantly
higher in BVS compared with EES/BES, reinforcing
our primary hypothesis of DES superiority within
the 6- to 12-month time frame. A possible explana-
tion for this difference may be the modest and
transient constrictive effect found at scaffold edges
(30). From a patient perspective, in-segment LLL is
meaningful because it encompasses the entire
treated lesion, including its edges. However, the
clinical impact of in-segment LLL is uncertain and
has not been clearly demonstrated for metallic
platforms. In DES, in-segment LLL has not corre-
lated with TLR as well as in-stent LLL (19,25). The
challenges in accurately detecting BVS edges make
in-stent—namely “in-scaffold”—LLL a complex and
uncertain measure. In-segment may therefore be
more sensitive than in-stent parameters. Although
we believe particular attention should be paid to
patients receiving BVS during the intermediate
phase and possibly up to 2 years, the accumulated
evidence of improved angiographic parameters 18 to
24 months after BVS implantation suggests a low
clinical impact of in-segment LLL.
Overall, the current data are reassuring and
demonstrate a satisfactory BVS safety proﬁle in all-
comer patients with broad clinical presentations.
This is of paramount importance given other pub-
lished data in all-comer patients (31,32) andthe continuous increase in BVS implantation
worldwide.
STUDY LIMITATIONS. Although the present pro-
spective study boasts a substantial rate of angio-
graphic follow-up, with few dropouts and the
unprecedented comparison of BVS with 2 of the
newest DES, it has several important limitations.
First, it is limited in size, with a primary angiographic
outcome, and was not powered to detect differences
in clinical event rates. Given the uncertainty around
point estimations, extrapolations should be drawn
with caution. Second, because it was conducted in a
single center with PCI performed by 5 operators with
uniform procedural strategies, generalizations to
other centers become limited. Third, a bias in
lesion selection and implantation technique for the
FIGURE 3 Composite Clinical Endpoints
EES BES BVS
1.00
0.75
0.50
0.25
0.00
0 100 200 300 365
Number
at risk
Number
at risk
EES
BES
BVS
80 80 80
80
78
78
78 78
78
44
47
49
42
45
48
Log-rank p-value = 0.2
1.00
0.75
0.50
0.25
0.00
0 100 200 300 365
EES
BES
BVS
80 76 75
80
78
78
78 75
78
36
43
39
32
38
39
Log-rank p-value = 0.14
Device-oriented Composite Patient-oriented Composite
Follow-up in DaysFollow-up in Days
The Kaplan-Meier curves demonstrate no signiﬁcant differences between the individual stent cohorts for either device- or patient-oriented
composite clinical endpoints. Device-oriented composite ¼ cardiac death, myocardial infarction of the target vessel, and target vessel
revascularization; patient-oriented composite ¼ all-cause mortality, any myocardial infarction, and any repeat revascularization.
Abbreviations as in Figure 1.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Short-term angiographic outcomes following deploy-
ment of the latest types of DES with BVS compare
favorably with those with late-generation DES.
TRANSLATIONAL OUTLOOK: Longer-term expe-
rience and evaluation of clinical outcomes are needed
to inform a better assessment of the comparative
beneﬁts of metallic versus BVS in patients undergoing
percutaneous coronary intervention.
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800BVS group cannot be excluded given the single-
blinded study design. Finally, we did not address
whether the bioabsorbable polymer in BES or the
bioresorbable vascular scaffold reduced thrombotic
risk.
CONCLUSIONS
New-generation metallic DES (EES/BES) were not
superior to BVS in terms of angiographic LLL. There
were no signiﬁcant differences between these devices
regarding clinical outcomes. The slight in-segment
LLL differences at 9 months deserve close clinical
follow-up during the 6- to 18-month period. Long-
term beneﬁt requires further investigation.
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